Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1553 results for do not do recommendations

  1. Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.

  2. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  3. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  4. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

  5. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  6. HTA Lab projects

    the environment. We're hoping to find a proportionate and pragmatic way to do this, bearing in mind that data and methods in this can...

  7. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

  8. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  9. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

  10. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  11. Breastfeeding support for parents with twins or triplets: What support with breastfeeding do parents of twins or triplets find helpful?

    Recommendation ID NG194/5 Question Breastfeeding support for parents with twins or triplets: What support with breastfeeding...

  12. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  13. Do primary care practitioners use NICE guidance when encouraging people to be physically active?

    Recommendation ID PH44/6 Question Do primary care practitioners use NICE guidance when encouraging people to be physically...

  14. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Recommendation ID PH43/9 Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the...

  15. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Recommendation ID PH43/10 Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the...